Regulatory approvals and strategic expansions drive market focus this morning. Tahmar Enterprises surges nearly 20% after securing permission to manufacture IMFL, while Mazagon Dock signs a major MoU for a greenfield shipyard cluster. Fortis Healthcare also makes headlines with a long-term hospital deal in Delhi.

Tahmar Enterprises

• Regulatory: The company received permission from Maharashtra Excise to manufacture Indian Made Foreign Liquor (IMFL) from grain-based spirit. Stock closed at ₹5.30 in the previous session, up 19.91%.
• Corporate action: The board will review expressions of interest for a distillery undertaking in Kolhapur during its September 21 meeting. Related-party Seebhal Distillery proposes purchasing non-core properties.

Infosys

• Product launch: Infosys inaugurated a 330,000-sq ft Software Development Block in Indore focused on AI, cloud, and cybersecurity capabilities. Stock closed at ₹1,060.00 in the previous session, down 1.58%.
• CSR: The Infosys Foundation granted ₹31 crore to Madras Medical College to establish a cardio-obstetric outpatient unit and catheterization lab in Chennai, aiming to reduce maternal mortality from cardiac complications.

Candour Techtex

• Deal: Signed an MoU with Ratanmoti Texfab to coat and laminate base fabrics for defence applications destined for DRDO's Aerial Delivery Research Establishment. Stock closed at ₹59.00 in the previous session, down 4.81%.
• Corporate action: The 40th AGM on September 29 seeks shareholder approval for a ₹12 crore inter-corporate deposit facility and the re-appointment of director Ms. Sharmila Hiralal Amin.

Mazagon Dock Shipbuilders

• Deal: Signed an MoU to act as the anchor shipyard for the Dighi Greenfield Shipbuilding Cluster in Maharashtra, targeting an annual capacity of 1.2 million Gross Tonnage. Stock closed at ₹2,231.90 in the previous session, down 0.18%.
• Management: Appointed K.M. Ravi Kumar as Non-Official (Independent) Director effective September 7, bringing 38 years of structural fabrication experience to the board.

Fortis Healthcare

• Deal: Signed a 29-year agreement for a 400-bed super specialty hospital in Ashok Vihar, New Delhi, expanding its Delhi-NCR footprint to over 3,400 beds via an asset-light model. Stock closed at ₹870.30 in the previous session, down 1.11%.
• Litigation: Filed an SLP in the Supreme Court challenging a Delhi High Court judgment regarding litigation with Daiichi Sankyo. Separately, a Tokyo court dismissed claims by NTK against Daiichi Sankyo, with NTK bearing full costs.

Tempsens Instruments

• Earnings: Q1FY27 consolidated net profit rose 14.3% year-on-year to ₹152 million, driven by a 78% surge in export revenue to ₹398 million. Stock closed at ₹540.55 in the previous session, up 3.23%.
• Guidance: EBITDA margin contracted to 20.59% from 23.61% due to ESOP charges. An earnings call is scheduled for September 17 to discuss financial results.

GR Infraprojects

• Litigation: Terminated Battery Energy Storage Systems (BESS) EPC contracts with NTPC with immediate effect and invoked the dispute resolution process. Stock closed at ₹819.05 in the previous session, down 2.28%.

Suratwwala Business Group

• Order Book: Subsidiary won a ₹69 crore EPC order for a 20MW AC solar plant in Maharashtra, representing 162% of average quarterly revenue. Stock closed at ₹21.49 in the previous session, up 0.75%.

Bottom Line

Strategic expansion dominates the news cycle, with defence and healthcare players securing long-term infrastructure deals. While large caps like Infosys focus on AI capacity, small-caps react sharply to regulatory nods and order wins, highlighting divergent growth drivers across market segments.